 Chairman, I offer an amendment.  The CHAIRMAN pro tempore. The Clerk will designate the amendment.  The text of the amendment is as follows:       Amendment Offered by Mr. Sanders: Page 88, after line 7,      insert the following new title:                TITLE VII--ADDITIONAL GENERAL PROVISIONS       Sec. 701. (a) Limitations on Use of Funds for Agreements      for Development of Drugs.--None of the funds made available      in this Act may be used by the Director of the National      Institutes of Health to enter into--       (1) an agreement on the conveyance or licensing of a patent      for a drug, or another exclusive right to a drug.       (2) an agreement on the use of information derived from      animal tests or human clinical trials conducted by the      National Institutes of Health on a drug, including an      agreement under which such information is provided by the      National Institutes of Health to another on an exclusive      basis; or       (3) a cooperative research and development agreement under      section 12 of the Stevenson-Wydler Technology Innovation Act      of 1980 (15 U.S.C. 3710a) pertaining to a drug.       (b) Exceptions.--Subsection (a) shall not apply when it is      made known to the Federal officer having authority to      obligate or expend the funds involved that--       (1) the sale of the drug involved is subject to a      reasonable price agreement; or       (2) a reasonable price agreement regarding the sale of such      drug is not required by the public interest.  The CHAIRMAN pro tempore. Pursuant to the order of the House of August 2, 1995, the gentleman from Vermont [Mr. Sanders] will be recognized for 10 minutes and a Member opposed will be recognized for 10 minutes.  The Chair recognizes the gentleman from Vermont [Mr. Sanders].                              {time}  2300  